期刊文献+

Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease

原文传递
导出
摘要 As obesity incidence increases worldwide,nonalcoholic fatty liver disease(NAFLD)has become the most common form of liver disease,with a reported global prevalence of 25.2%(1).Nonalcoholic steatohepatitis(NASH)is a severe form of NAFLD.However,the precise natural history of NAFLD/NASH remains unclear.NASH is rapidly becoming the leading cause of end-stage liver disorders and liver transplants and is associated with increased cardiovascular disease risk(2).As a result,it poses critical health issues globally from both medical and socioeconomic perspectives.
出处 《Hepatobiliary Surgery and Nutrition》 SCIE 2022年第3期433-435,共3页 肝胆外科与营养(英文)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部